Medtronic’s IN.PACT AV Drug-Coated Balloon Receives the US FDA’s Approval for the Treatment of Arteriovenous Fistula Lesions

 Medtronic’s IN.PACT AV Drug-Coated Balloon Receives the US FDA’s Approval for the Treatment of Arteriovenous Fistula Lesions

Medtronic’s IN.PACT AV Drug-Coated Balloon Receives the US FDA’s Approval for the Treatment of Arteriovenous Fistula Lesions

Shots:

  • The US FDA approval is based on IDE study assessing IN.PACT AV DCB vs percutaneous transluminal angioplasty in 330 patients with end-stage renal disease (ESRD) undergoing dialysis at 29 sites in the US, Japan, and New Zealand
  • The study showed that IN.PACT AV DCB maintained AV access site patency and required 56% fewer reinterventions @6mos., similar mortality rate @12mos., later demonstrated superior patency in both de novo and restenotic lesions and all studied types of AV access
  • Medtronic’s IN.PACT AV DCB utilizes its Admiral platform act by increasing the blood flow and reducing thickening of the vessel wall by delivering the proven anti-proliferative drug paclitaxel and has received CE Mark indication in 2016

Click here to­ read full press release/ article | Ref: Medtronic | Image: Vascular News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post